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ABSTRACT Cerebral malaria (CM) is a potentially deadly outcome of Plasmodium
falciparum malaria that is precipitated by sequestration of infected erythrocytes (IEs)
in the brain. The adhesion of IEs to brain endothelial cells is mediated by a subtype
of parasite-encoded erythrocyte membrane protein 1 (PfEMP1) that facilitates dual
binding to host intercellular adhesion molecule 1 (ICAM-1) and endothelial protein
receptor C (EPCR). The PfEMP1 subtype is characterized by the presence of a particu-
lar motif (DBL_motif) in the constituent ICAM-1-binding DBL domain. The rate of
natural acquisition of DBL_motif-speciﬁc IgG antibodies and the ability to induce
such antibodies by vaccination are unknown, and the aim of this study was to pro-
vide such data. We used an enzyme-linked immunosorbent assay (ELISA) to measure
DBL-speciﬁc IgG in plasma from Ghanaian children with malaria. The ability of hu-
man immune plasma and DBL-speciﬁc rat antisera to inhibit the interaction be-
tween ICAM-1 and DBL was assessed using ELISA and in vitro assays of IE adhesion
under ﬂow. The acquisition of DBL_motif-speciﬁc IgG coincided with age-speciﬁc
susceptibility to CM. Broadly cross-reactive antibodies inhibiting the interaction be-
tween ICAM-1 and DBL_motif domains were detectable in immune plasma and in
sera of rats immunized with speciﬁc DBL_motif antigens. Importantly, antibodies
against the DBL_motif inhibited ICAM-1-speciﬁc in vitro adhesion of erythrocytes
infected by four of ﬁve P. falciparum isolates from cerebral malaria patients. We con-
clude that natural exposure to P. falciparum as well as immunization with speciﬁc
DBL_motif antigens can induce cross-reactive antibodies that inhibit the interaction
between ICAM-1 and a broad range of DBL_motif domains. These ﬁndings raise
hope that a vaccine designed speciﬁcally to prevent CM is feasible.
KEYWORDS DBL cross-reactive antibodies, ICAM-1-binding motif, PfEMP1,
Plasmodium falciparum, adhesion inhibition
Plasmodium falciparum is the major cause of the estimated 430,000 deaths due tomalaria that are reported annually (1). The pathogenesis of P. falciparum is
linked to sequestration of infected erythrocytes (IEs) in various tissues, which can
lead to tissue-speciﬁc inﬂammation, circulatory obstruction, and organ dysfunction
(reviewed in reference 2). IE sequestration is mediated by members of the ery-
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throcyte membrane protein 1 (PfEMP1) family. These proteins are encoded by
approximately 60 var genes per P. falciparum genome and are expressed on the IE
surface, where they bind to a range of host receptors (reviewed in reference 3).
Despite extensive inter- and intraclonal diversity, the PfEMP1 proteins can be
classiﬁed into three major groups (A, B, and C), based on var gene sequence and
chromosomal context (4, 5). Group A is less diverse than the other groups, and
expression of group A PfEMP1 proteins on the IE surface has repeatedly been linked to
the development of severe malaria (6, 7). This is consistent with the restricted serolog-
ical diversity of P. falciparum parasites from patients with severe malaria (8, 9). It also ﬁts
the observation that acquisition of immunity to complicated disease often precedes
development of protection from uncomplicated malaria and asymptomatic parasitemia
and that PfEMP1 expression is modulated by PfEMP1-speciﬁc immunity (10–12). More
recently, the PfEMP1 groups have been further subdivided according to their constit-
uent Duffy-binding-like (DBL) and cysteine-rich interdomain region (CIDR) domains, and
a number of multidomain blocks, known as domain cassettes (DCs), have been iden-
tiﬁed (13–16). Three of these, DC4, DC8, and DC13, have been linked to severe malaria
in children (6, 14, 17, 18). DC4 consists of three domains (DBL1.1/1.4, CIDR1.6, and
DBL3) and deﬁnes a subfamily of group A PfEMP1 proteins that mediates binding to
intercellular adhesion molecule 1 (ICAM-1) (15). IE adhesion to ICAM-1 appears asso-
ciated with severe malaria, implicating DC4-speciﬁc antibodies in clinical protection, as
they are acquired early in life by children living in areas where malaria is endemic and
are associated with clinical protection from malaria (6, 15, 19). However, until recently,
the role of IE adhesion to ICAM-1 speciﬁcally in CM has been unclear (20–24).
DC8 consists of four domains (DBL2, CIDR1.1, DBL12, and DBL4/6) and is found
among group B/A genes, while the two-domain (DBL1.7, CIDR1.4) DC13 is found in
some group A PfEMP1 proteins (14). Endothelial protein receptor C (EPCR) is the
cognate receptor for DC8- and DC13-containing PfEMP1 proteins (25). Some studies
have reported high transcript levels of var genes encoding EPCR-binding PfEMP1
variants in parasites from children with severe malaria, including CM, and perturbed
EPCR expression in brain tissue of CM patients (26–28). While these ﬁndings point to a
role for EPCR in severe malaria in general, and cerebral malaria (CM) in particular, the
available evidence overall remains equivocal (29–31).
We have previously proposed that the above ambiguities may reﬂect that the
pathogenesis of CM involves P. falciparum parasites expressing PfEMP1 capable of
mediating IE adhesion to both ICAM-1 (via DBL) and EPCR (via CIDR1) (3). A few such
dual receptor-binding PfEMP1 proteins were identiﬁed shortly after, although the study
did not link them to CM speciﬁcally and did not document concomitant binding to
both receptors (32). However, those gaps were recently closed by our demonstration of
a link between CM and group A PfEMP1 proteins capable of binding ICAM-1 and EPCR
simultaneously (33). This dual receptor-binding subgroup of PfEMP1 proteins is char-
acterized by an EPCR-binding CIDR1 domain followed immediately by a DBL domain
featuring a speciﬁc ICAM-1-binding motif (DBL_motif domain) (33).
The rate of natural acquisition of IgG against the DBL_motif associated speciﬁcally
with CM and the ability to induce such antibodies by vaccination are both unknown.
The current study was therefore designed to investigate whether cross-reactive IgG
antibodies speciﬁc for DBL_motif domains and/or their ICAM-1-binding motif are
acquired following natural exposure to P. falciparum parasites and whether ICAM-1
adhesion inhibitory antibodies can be induced by immunization with speciﬁc
DBL_motif proteins and with peptides representing the ICAM-1-binding motif therein.
Conﬁrmation of these hypotheses would support the feasibility of developing a vaccine
designed speciﬁcally to prevent CM.
RESULTS
Delayed acquisition of IgG to ICAM-1-binding group A-type DBL domains.
Group A PfEMP1 proteins that contain a DBL domain with the motif I(V/L)X3N(E)GG
(P/A)XYX27GPPX3H (DBL_motif domains) (where X represents an unknown amino
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acid) can bind to the host endothelial receptor ICAM-1 and always feature a neighbor-
ing CIDR1 domain that enables concomitant binding to another endothelial receptor,
EPCR (33). Expression of these dual receptor-binding PfEMP1 proteins is associated with
CM, which is a major cause of mortality and severe morbidity among African children.
The age at which most CM cases occurs varies with transmission intensity but generally
occurs later than the peak prevalence of parasitemia and malaria-related severe ane-
mia. DBL domains present in group A PfEMP1 proteins, but without the above motif
(DBL_nonmotif domains), do not bind ICAM-1 and are less conserved in the C
terminus (33).
We ﬁrst used ELISA to measure the levels of IgG with speciﬁcity for 14 recombinant
DBL_motif domains (M1 to M12, M14, and M15) (Fig. 1) and 13 nonmotif DBL
domains (N20 to N32) in plasma from 79 Ghanaian children with different clinical
presentations of P. falciparum malaria (Table 1). The antibody reactivity to all these
group A PfEMP1 proteins differed substantially among the children (Fig. 2A) and also
among the different DBL domains (Fig. 2B). Overall, the plasma levels of IgG increased
with age (Pr  0.001, where r is Pearson’s product moment correlation), with levels of
IgG speciﬁc for DBL_motif proteins being generally lower than those of DBL_nonmotif-
speciﬁc IgG (PT 0.001, where T is the Kruskal-Wallis one-way analysis of variance on ranks).
However, the latter difference was due mainly to low IgG recognition of the DBL_motif
among the younger age groups (4 years of age) (Fig. 2C). Thus, the levels of IgG speciﬁc
for the DBL_motif were signiﬁcantly lower than the DBL_nonmotif-speciﬁc IgG levels
among children aged 1 to 2 years and 3 to 4 years (PT  0.001), but not in the two older
age classes considered (5 to 6 years and 6 years; PT  0.21).
The overall plasma levels of IgG speciﬁc for DBL_motif domains as well as
DBL_nonmotif domains were similar in patients with severe and uncomplicated
malaria (PU  0.4 in both cases, where U is the Mann-Whitney test for intergroup
differences), while levels of DBL_nonmotif domain-speciﬁc IgG were lower in the
children with severe malaria than in the patients with uncomplicated disease (scores, 7
and 12.5; PU  0.02, respectively).
Taken together, these results indicate that DBL_motif and DBL_nonmotif proteins
are similarly immunogenic but that DBL_motif-speciﬁc IgG is acquired later in life than
DBL_nonmotif-speciﬁc IgG.
Immunization with DBL_motif antigens induces cross-reactive, neutralizing
IgG. Plasma from clinically immune individuals living in areas of stable and intense
transmission of P. falciparum parasites can inhibit the interaction between ICAM-1 and
a range of DBL_motif domains (15, 33). In this study, a pool of plasma from 10 of the
children (selected for reactivity with DBL_motif domains [Fig. 2A and Table 1] and
plasma availability) inhibited ICAM-1 binding to DBL_motif protein M9 (Fig. 3A). These
data suggest the presence of neutralizing IgG antibodies capable of recognizing
multiple DBL_motif-containing PfEMP1 variants (cross-reactive IgG). If such antibodies
could be induced by vaccination, it would increase the feasibility of developing a
broadly protective PfEMP1-based vaccine against cerebral malaria. However, our data
might also reﬂect the presence of many different variant-speciﬁc IgG speciﬁcities,
where each antibody speciﬁcity is capable of inhibiting the binding of ICAM-1 to only
FIG 1 Sequence logo showing the ICAM-1-binding motif (as deﬁned in reference 33) of DBL domains 1 to 15 used in the present study (Table 3). Residues
that are critical for the direct interaction with ICAM-1 (red triangles) or for the architecture of the ICAM-1 binding (white triangles) are indicated. The group
A PfEMP1 ICAM-1-binding motif was identiﬁed by Lennartz et al. (33).
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a particular DBL_motif domain variant (a broad repertoire of IgG with narrow speci-
ﬁcity). It is inherently difﬁcult to distinguish between these two alternatives in naturally
acquired immunity. Nevertheless, truly cross-reactive PfEMP1-speciﬁc human antibod-
ies have previously been demonstrated in a study employing naturally acquired
monoclonal IgG speciﬁc for the VAR2CSA-type PfEMP1 involved in the pathogenesis of
placental malaria (34).
To investigate the relative importance of the above nonexclusive alternatives, to
further assess the functional signiﬁcance of DBL_motif in acquired immunity, and to
FIG 2 Plasma levels of IgG with speciﬁcity for P. falciparum DBL domains. Samples were obtained from 79 Ghanaian children with either severe
(Œ) or nonsevere P. falciparum malaria. (A) Levels (ELISA units [EU]) in plasma from individual children (columns) of IgG antibodies speciﬁc for
individual group A DBL domains (rows) containing (DBL_motif; M1 to M12, M14, and M15) or not containing (DBL_nonmotif; N20 to N32;
lower half) the ICAM-1-binding motif identiﬁed by Lennartz et al. (33). Shading indicates IgG level score: black, score of 4 (100 EU); dark gray,
score of 3 (76 to 100 EU); gray, score of 2 (51 to 75 EU); light gray, score of 1 (26 to 50 EU); white, score of 0 (0 to 25 EU). The DBL domain numbers
correspond to the numbers in Table 3. Danish controls (n  25) did not react with any of the domains (data not shown). (B) The means of IgG
level scores (deﬁned as described for panel A) of individual DBL domains that contain (motif; Œ) or do not contain (nonmotif; ) the
ICAM-1-binding motif. Error bars indicate 95% conﬁdence intervals. DBL domain numbering is as described for panel A. (C) The means of IgG
level scores (deﬁned as described for panel A) of individual children for IgG speciﬁc for DBL_motif (Œ) and DBL_nonmotif () domains. The
statistical signiﬁcance (Mann-Whitney rank sum test) of pairwise comparisons is shown along the top of the panel.
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make a ﬁrst step toward PfEMP1-based vaccination speciﬁcally against cerebral malaria,
we immunized four rats with DBL_motif proteins M1, M6, M9, and M10, respectively
(see Table 3; see also Fig. S1 in the supplemental material). We used an enzyme-linked
immunosorbent assay (ELISA) to test the ability of the antisera to inhibit the binding of
ICAM-1 to 14 DBL_motif proteins (M1 to M7 and M9 to M15) and two ICAM-1-binding
DBL_nonmotif proteins (N27 and N33). Each of the four DBL_motif-speciﬁc antisera
inhibited binding of ICAM-1 to most of the DBL_motif proteins by more than 50% but
had little effect on ICAM-1-binding to DBL_nonmotif domains (Fig. 3B). When pooled,
the DBL_motif-speciﬁc antisera strongly inhibited (75%) binding of ICAM-1 to all
DBL_motif domains, with much less effect (50%) on ICAM-1-binding to the
DBL_nonmotif domains (Fig. 3B). We next afﬁnity puriﬁed IgG from three of the rat
antisera, using M6pep, to evaluate the involvement of IgG directly targeting the
ICAM-1-binding region in the above-described inhibition. The puriﬁed M6pep-speciﬁc
IgG generally inhibited ICAM-1 binding to the same degree as the antisera (Fig. 3B),
with strong correlation between the antiserum and motif-speciﬁc IgG data for M6
(Spearman’s rank order correlation [rs]  0.78; P  0.001).
Overall, these data indicate that immunization with single DBL_motif antigens can
induce cross-reactive IgG that inhibits binding of ICAM-1 to the homologous, as well as
a broad range of heterologous, DBL_motif domains.
DBL_motif-speciﬁc IgG is broadly inhibitory of IE adhesion to ICAM-1 under
physiologic ﬂow. The ability of neutralizing IgG to interfere with receptor-speciﬁc IE
sequestration in vivo likely depends on the characteristics of the involved PfEMP1
proteins per se, on their expression on the IE surface, and on the shear forces at the
anatomical location of the interaction of IEs with host endothelium. We have previously
shown that naturally acquired IgG can inhibit ICAM-1-speciﬁc adhesion of erythrocytes
infected by P. falciparum expressing DBL_motif-containing PfEMP1 (33). To test if such
antibodies could also be elicited by immunization with recombinant PfEMP1 proteins
containing the DBL_motif, we tested the ability of DBL_motif-speciﬁc IgG to inhibit
the adhesion of IEs to ICAM-1 in an in vitro assay simulating physiologic ﬂow conditions
(35). M6-speciﬁc IgG signiﬁcantly inhibited ICAM-1-speciﬁc adhesion of IEs expressing
FIG 3 Ability of DBL_motif-speciﬁc IgG to inhibit binding of ICAM-1 to DBL domains. (A) Inhibition of
ICAM-1 binding by pooled immune plasma from 10 of the study children (pool). ***, PF  0.001. (B) Rat
antisera raised against DBL_motif antigens tested against recombinant proteins containing (M1 to M7
and M9 to M15) or not containing (N27 and N33) the DBL_motif. Shading indicates the degree of
inhibition: black, 75%; dark gray, 50 to 75%; gray, 20 to 50%; white, 20%. The DBL domain numbers
and antiserum speciﬁcities correspond to the data in Table 3. Data using a pool of rat antisera (M1, M6,
M9, M10) are also shown (pool). Antisera marked with asterisks were afﬁnity puriﬁed on a peptide
(M6pep) representing the binding motif in PFD1235w_DBL_D4 prior to assaying. Three independent
experiments were done (three technical replicates/assay). A sequence-distance tree illustrating the
relatedness of the different domains is shown along the left edge of the panel.
Olsen et al. Infection and Immunity
April 2018 Volume 86 Issue 4 e00622-17 iai.asm.org 6
 o
n
 M
ay 23, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
the homologous PfEMP1 (PFD1235w; PF  0.001, where F is one-way analysis of
variance) (Fig. 4A) or a heterologous PfEMP1 (HB3VAR03; PF  0.001) (Fig. 4B). This was
also the case for IgG speciﬁc for M9 and M10 (see Table 3) and IgG puriﬁed on the
ICAM-1-binding motif in M6 (M6pep; PF  0.001). The M9-speciﬁc antibodies also
affected ICAM-1-speciﬁc adhesion of IEs expressing IT4VAR13, a group B PfEMP1
protein that binds ICAM-1 but does not contain the DBL_motif (see reference 33) (Fig.
4C). Conversely, an antiserum to the ICAM-1-binding domain in IT4VAR13 (N27) inhib-
ited ICAM-1-speciﬁc adhesion of the homologous IEs (Fig. 4C) but had no effect on
ICAM-1-speciﬁc adhesion of IEs expressing the DBL_motif-containing PfEMP1 protein
PFD1235w (Fig. 4A) or HB3VAR03 (Fig. 4B).
We conclude from these experiments that immunization with DBL_motif antigens
induces cross-reactive IgG antibodies that inhibit ICAM-1-speciﬁc adhesion of IEs that
express a variety of PfEMP1 proteins containing DBL_motif domains. The inhibition of
binding of native PfEMP1 protein to ICAM-1 under conditions of ﬂow thus mirrors that
observed with recombinant proteins in ELISA.
Immunization with peptides representing the ICAM-1-binding region induces
antibodies broadly inhibiting the binding of recombinant and native DBL_motif
domains to ICAM-1. The results above suggested that IgG targeting the ICAM-1-
binding region in DBL_motif domains is of particular importance for inhibiting the
binding of group A dual receptor-binding PfEMP1 to ICAM-1. This interpretation is
further supported by our recent data showing that DBL_motif-puriﬁed antibodies
from naturally infected humans and experimentally vaccinated animals inhibit ICAM-
1-speciﬁc adhesion of IEs expressing the DBL_motif-containing PfEMP1 protein
PFD1235w (33). To assess directly if inhibitory and cross-reactive antibodies could be
elicited by peptide immunization, we immunized rats with peptides representing the
ICAM-1-binding region in DBL_motif domains (M6pep and M9pep) and tested their
ability to inhibit binding of ICAM-1 to DBL_motif domains. Antisera from rats immu-
nized with M6pep only, or with M6pep and M9pep, were broadly inhibitory of the
binding of ICAM-1 to 10 DBL_motif domains (M2 to M7, M9, and M11 to M13). The
peptide antisera did not affect binding to two ICAM-1-binding DBL_nonmotif do-
mains (N27 and N33) (Fig. 5A). Experiments assessing the ability of the antisera to
inhibit the adhesion of IEs to ICAM-1 under ﬂow corroborated these ﬁndings. Thus,
both of the above-mentioned antisera (M6pep and M6pep/M9pep) signiﬁcantly inhib-
ited the adhesion of IEs expressing the DBL_motif-containing PfEMP1 proteins
PFD1235w (Fig. 5B) (expressing M6 native protein) and HB3VAR03 (Fig. 5C) (expressing
M8 native protein) but had no effect on IEs expressing IT4VAR13 (expressing N27 native
protein), which does not contain a DBL_motif domain (Fig. 5D). Furthermore, the
single- and dual-peptide antisera yielded immunoﬂuorescence patterns typical of IgG
reacting with IE surface-expressed PfEMP1 when tested against IEs expressing either
HB3VAR03 or PFD1235w but did not label IEs expressing IT4VAR13 (Fig. 5E). In contrast,
the IEs expressing IT4VAR13 were labeled by an IT4VAR13-speciﬁc antiserum but not by
the single- and dual-peptide antisera (Fig. 5E).
Finally, we assessed the ability of erythrocytes infected by 33 primary P. falciparum
isolates (Table 2) from Ghana (n 14) and Tanzania (n 19) to adhere to ICAM-1 under
ﬂow. We also tested the ability of pooled rat antiserum to M6pep and M9pep to inhibit
the adhesion of ICAM-1-adhering isolates. Twenty-two of the isolates (3 from children
with uncomplicated malaria, 14 from patients with severe malaria, and 5 from children
with cerebral malaria) showed adhesion of IEs to ICAM-1 (Fig. 6A). The adhesion of 11
of these isolates (1 from a child with uncomplicated malaria, 6 from children with
severe malaria, and 4 from children with cerebral malaria) was inhibited (25%) by the
anti-peptide serum pool (Fig. 6B).
We conclude that immunization with linear peptides that represent only the ICAM-
1-binding region of speciﬁc DBL_motif domains can induce cross-reactive antibodies
that are capable of inhibiting the binding of ICAM-1 to a range of recombinant and
native, IE-expressed DBL_motif domains. Importantly, the motif antibody inhibits the
binding of four of ﬁve P. falciparum isolates from cerebral malaria patients.
Cross-Reactive IgG Inhibits CM Type IE Adhesion to ICAM-1 Infection and Immunity
April 2018 Volume 86 Issue 4 e00622-17 iai.asm.org 7
 o
n
 M
ay 23, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
FIG 4 DBL-speciﬁc antibody-mediated inhibition of adhesion of IEs to ICAM-1 under physiologic shear
stress, relative to that of control without antibody (none). (A) IEs expressing PFD1235w; (B) IEs expressing
HB3VAR03; (C) IEs expressing IT4VAR13. The speciﬁcities of the DBL antibodies correspond to the data
in Table 3. The antiserum marked with an asterisk was afﬁnity puriﬁed on a peptide (M6pep) representing
the binding motif in PFD1235w DBL_D4 prior to assaying. An ICAM-1-speciﬁc neutralizing antibody
(Continued on next page)
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DISCUSSION
Cerebral malaria (CM) is one of the most severe complications of P. falciparum
malaria and a leading cause of mortality (reviewed in reference 36). PfEMP1-mediated
adhesion of IEs to the endothelial receptors ICAM-1 and EPCR have both repeatedly
been implicated in the pathogenesis of severe malaria (15, 25, 33). However, a speciﬁc
and direct link to the development of CM has been missing until recently, when we
identiﬁed a sequence motif in PfEMP1 proteins associated speciﬁcally with the devel-
opment of CM (33). This ICAM-1-binding motif (DBL_motif) (Fig. 1) is found in some
group A PfEMP1 proteins (15), immediately downstream of an EPCR-binding CIDR
domain (25). In the present study, we set out to study the acquisition of DBL_motif-
speciﬁc IgG following natural exposure and whether DBL_motif-speciﬁc antibodies
induced by vaccination are cross-reactive and inhibit adhesion to ICAM-1.
In areas with stable transmission of these parasites, substantial protective immunity
to malaria is acquired during childhood, ﬁrst to severe complications and later to
clinical disease. As a consequence, adults are largely protected from malaria in such
areas, although sterile immunity is rarely, if ever, achieved. This sequence appears to be
the consequence of an ordered acquisition of antibodies to a relatively conserved set
of PfEMP1 proteins associated with severe disease, followed by antibodies to a large
and diverse set of PfEMP1 proteins associated with uncomplicated malaria and asymp-
tomatic parasitemia. Where transmission is very intense, serious and fatal malaria
episodes are markedly concentrated during the ﬁrst few years of life, mainly as severe
malarial anemia. CM, in contrast, is rare (37). Where endemicity is lower, CM tends to be
seen more often but mainly among children some years older than those that succumb
to severe malarial anemia. Together these ﬁndings suggest that discrete PfEMP1
subsets are involved in severe malaria with and without cerebral involvement and
perhaps even that toddlers are relatively resistant to CM for nonimmunologic reasons.
This ﬁts our demonstration here that although DBL domains are generally immuno-
genic following natural exposure, acquisition of DBL_motif-speciﬁc IgG occurs later
than that of DBL_nonmotif-speciﬁc IgG (Fig. 2) and coincides with the age bracket in
which the incidence of CM peaks under transmission intensities comparable to those in
our study area (38, 39).
The clinical signiﬁcance of acquisition of PfEMP1-speciﬁc antibodies is thought to
involve their ability to interfere with sequestration of IEs in various tissues (15, 40). A
particularly thoroughly investigated example is the role of anti-adhesion antibodies in
the acquisition of protective immunity to placental P. falciparum malaria, caused by
accumulation of IEs in the intervillous spaces (41, 42). Placental IE sequestration is
mediated by a particular group of PfEMP1 (VAR2CSA) binding to oncofetal chondroitin
sulfate A (43, 44), and clinical trials of vaccines based on the VAR2CSA adhesive epitope
and aimed to protect against this important cause of prenatal and infant morbidity and
mortality are under way. It appears that DBL_motif-speciﬁc IgG can inhibit IE adhesion
to ICAM-1 in a similar way (Fig. 3A) (15, 33). Here, we demonstrate that this inhibition
can be mediated by genuinely cross-reactive antibodies, as opposed to a broad
repertoire of IgG species, each with narrow speciﬁcity for a single or very few
DBL_motif sequences (Fig. 3). This ﬁnding is of signiﬁcance, since naturally acquired
protection from malaria is generally believed to be the consequence of the accumu-
lation of a broad repertoire of a large number of antibody speciﬁcities (9, 12, 45). Such
broadly reactive IgG can inhibit the adhesion of erythrocytes infected with parasites
isolated from patients with severe malaria (6 of 13 isolates) and cerebral malaria (4 of
5 isolates) under physiologic ﬂow conditions (Fig. 6). Furthermore, such IgG can be
FIG 4 Legend (Continued)
(ICAM-1) and an irrelevant rat anti-IgG (Sigma-Aldrich) were included as positive and negative controls,
respectively. Fewer than 0.25 IEs/mm2 bound to uncoated channels. Means (bars) and standard devia-
tions (error bars) of the results of at least three independent experiments in triplicate are shown.
Statistically signiﬁcant reductions relative to adhesion in the absence of antibody () are indicated above
the bars (**, PF  0.01; ***, PF  0.001). See Table S1 in the supplemental material for raw data.
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FIG 5 Ability of rat antisera to the ICAM-1-binding motif in DBL_motif domains to inhibit binding of
recombinant DBL domains to ICAM-1. (A) Antisera from rats immunized with M6pep or with both
M6pep and M9pep tested against recombinant DBL_motif domains (M2 to M7, M9, and M11 to M13)
and DBL_nonmotif domains (N27 and N33). Shading, DBL domain numbers, and antiserum speciﬁc-
ities are as described in the legend to Fig. 3B. (B to D) Inhibition by the same antisera of ICAM-1-speciﬁc
adhesion of PFD1235w-positive IEs (B), HB3VAR03-positive IEs (C), and IT4VAR13-positive IEs (D) under
physiologic shear stress. The statistical signiﬁcance of the reductions is indicated as described in the
legend to Fig. 4. Three independent experiments were done (with three technical replicates in each).
(Continued on next page)
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induced by peptides (M6pep and M9pep) representing just the core element of the
DBL_motif that mediates the binding to ICAM-1 (Fig. 5 and 6).
Approximately half the children with acute P. falciparum malaria in our study had
severe disease, according to the WHO criteria (46), but we did not observe any
signiﬁcant differences in plasma levels of DBL_motif-speciﬁc IgG in children with or
without severe disease. This may be related to the fact that due to the low prevalence
in the area none of the study children had CM (Table 1). It is doubtful that a relationship
between DBL_motif-speciﬁc IgG and clinical presentation of acutely ill malaria pa-
tients would be apparent, even if we had been able to include plasma samples from CM
patients, due to the unavoidable variation in time between infection and presentation
to hospital. It is plausible that only very large, and preferably longitudinal, studies
would have the power required to document such relationships in semi-immune,
naturally infected individuals.
In conclusion, our study demonstrates that CM-related DBL domains are immuno-
genic following natural exposure and that acquisition of DBL_domain-speciﬁc IgG
coincides with the age where CM has its peak prevalence in areas of moderate but
stable P. falciparum transmission. Furthermore, we show that immunization with such
domains in addition to peptides representing the minimal ICAM-1-binding region can
induce IgG that can inhibit PfEMP1 binding to ICAM-1 and neutralize IE adhesion under
physiologic ﬂow. Importantly, these antibodies broadly neutralized the adhesion of
erythrocytes infected by parasites isolated from four of ﬁve children with cerebral
malaria. Together, these ﬁndings raise hopes that development of a vaccine speciﬁcally
against CM may be possible, despite the notorious polymorphism and intraclonal
diversity of the PfEMP1 family (recently reviewed in references 3 and 47).
MATERIALS AND METHODS
Plasma and parasite samples. Plasma samples (n 79) for the present study were collected in 2014
at Hohoe Municipality Hospital in the Volta Region of Ghana from children with acute malaria (Table 1)
(33, 48).
P. falciparum parasites were collected at this hospital (n  14) and at the Korogwe District Hospital
(n  19) in Korogwe District in northeastern Tanzania (14). Clinical manifestations of malaria were
classiﬁed according to the deﬁnitions and associated criteria of the World Health Organization. Patients
were categorized as having cerebral malaria (CM; n 7) if they had a positive blood smear of the asexual
form of P. falciparum and unrousable coma (Blantyre coma score [BCS]  2) with exclusion of other
causes of coma and severe illness. Patients were categorized as having severe malarial anemia (SA; n 
12) if the hemoglobin level was 5 g/dl and the BCS was 2. Patients were classiﬁed as having severe
malaria other than SA and CM if they presented with hyperparasitemia (250,000 parasites/l), multiple
convulsions (2 episodes in 24 h), respiratory distress (i.e., rapid, deep, and labored breathing), or
combinations of these symptoms. Patients with uncomplicated malaria (UM; n  48) had fewer than
250,000 parasites/l.
The study was approved by the Ethical Review Committee of the Ghana Health Services (ﬁle GHS-ERC
08/05/14) and by the National Ethical Review Committee of the National Institute for Medical Research,
Tanzania (NIMR/HQ/R.8a/Vol.IX/559). A pool of plasma from P. falciparum-exposed Tanzanian individuals
(49) and 25 nonexposed Danish individuals were used as positive and negative controls, respectively.
Long-term in vitro culture-adapted and fully sequenced parasite clones 3D7, HB3, and IT4 were also
studied.
Recombinant proteins. The genes encoding the DBL domains used were ampliﬁed from genomic
DNA or produced as synthetic genes (http://euroﬁns.dk) (Table 3). Amplicons were subcloned into a
modiﬁed pET15b vector and expressed as His-tagged proteins in Escherichia coli Shufﬂe C3030 cells (New
England BioLabs) as described previously (15). All the proteins were puriﬁed (see Fig. S1 in the
supplemental material) by immobilized metal ion afﬁnity chromatography using HisTrap HP 1-ml
columns (GE Healthcare) and are referred to by the designations listed in Table 3.
Recombinant Fc-tagged ICAM-1 was expressed in HEK293 cells and puriﬁed on a HiTrap Protein G HP
column (http://www3.gehealthcare.dk/) as described previously (50).
DBL-speciﬁc antisera. We generated rat antisera to recombinant proteins M1, M6, M9, M10, N27,
and N33 (Table 3) and to two synthetic peptides (Schafer-N) that corresponded to the ICAM-1-binding
FIG 5 Legend (Continued)
Fewer than 0.25 IEs/mm2 bound to uncoated channels were observed. (E) Immunoﬂuorescence of
representative IEs with surface expression of PFD1235w (top row), HB3VAR03 (center row), and IT4VAR13
(bottom row) and labeled by sera from rats immunized with M6pep only (left column) or with both
M6pep and M9pep (center column), or by a rat antiserum to N27 (right column). See Table S2 in the
supplemental material for raw data.
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motifs in M6 (M6pep, LYAKARIVASNGGPGYYNTEVQKKDRSVYDFLYELHLQNGGKKGPPPATHPYKSVNTRDKR
DATDDTTP) and M9 (M9pep, LYKEAEIYARNGGPGYYNTEVQKEDKPVVDFLYELHLQNGGKKGPPAATHPSKSVT
TRVKRDTTVDTPS). M1, M6, M9, and M10 were selected from different branches of the previously
published phylogenetic tree of DBL domains, to represent dual ICAM-1- and EPCR-binding group A
PfEMP1 proteins (33). In a similar way, N27 and N33 were chosen as random examples of ICAM-1-binding
group B PfEMP1 proteins.
In each case, Wistar rats were immunized with the antigen (25 g) in Freund’s incomplete adjuvant,
followed by two booster vaccinations 2 weeks apart (15 g/boost). Blood was collected 2 weeks after the
last immunization. All animal procedures were approved by the Danish Animal Procedures Committee
(“Dyreforsøgstilsynet”) as described in permit no. 2013-15-2934-00920, and all experiments were done
according to the guidelines described in Danish act LBK 1306 (23 November 2007) and BEK 1273 (12
December 2005).
IgG puriﬁcation. IgG antibodies speciﬁc for M6 and M6pep were afﬁnity puriﬁed from rat antisera
as described previously (51). In brief, M6 and M6pep (1 mg/ml) were dialyzed overnight against coupling
buffer and coupled to HiTrap normal human serum (NHS)-activated HP columns, as described by the
manufacturer (GE Healthcare). Antisera were diluted 1:1 in phosphate-buffered saline (PBS) and afﬁnity
puriﬁed on the columns, followed by elution of bound IgG in low-pH buffer (glycine-HCl, pH 2.75) and
pH adjustment by Tris-HCl (1 M, pH 9.0).
Measurements of DBL-speciﬁc IgG levels.MaxiSorp microtiter plates (Sigma-Aldrich) were coated
with recombinant DBL domains (50 l; 5 g/ml) as described previously (15). Plasma samples (diluted
1:100 in blocking buffer) were incubated (50 l/well, 1 h, room temperature) in duplicate wells. The
plates were washed (PBS plus 1% Triton X-100), and bound antibody was detected with horseradish
peroxidase (HRP)-conjugated anti-human IgG (1:3,000 in blocking buffer) (Agilent). After incubation (1 h)
and washing as described above, bound detection antibody was detected using o-phenylenediamine
dihydrochloride (OPD) tablets, according to the manufacturer’s instructions (Agilent). The optical density
(OD) values were read at 490 nm using a VERSAmax microplate reader (Molecular Devices). Antibody
reactivity was expressed in arbitrary ELISA units (EU) calculated by the equation (ODsample  ODbackground)/
(ODpositive control  ODbackground)  100 (52).
Measurements of antibody-mediated inhibition of DBL binding to ICAM-1. Inhibition of
recombinant DBL domain binding to ICAM-1 by human immune plasma and rat antisera was measured
by ELISA. In brief, wells of MaxiSorp plates were coated with recombinant ICAM-1 (50) (50 l/well, 2 or
4 g/ml, 0.1 M glycine-HCl buffer, pH 2.75) by incubation overnight (4°C) and blocked with blocking
buffer (1 h, room temperature). His-tagged DBL proteins (0.5 to 16 g/ml ﬁnal concentration) were
mixed with immune plasma or antisera (1:5 ﬁnal concentration) or puriﬁed IgG (10 g/ml ﬁnal concen-
tration) and added to duplicate wells (1 h, room temperature). The plates were washed, and binding was
detected using HRP-conjugated anti-penta-His antibody (Qiagen) as described above. All antisera were
prescreened by ELISA to verify the absence of His tag-reactive antibodies.
In vitro culture and antibody selection of P. falciparum parasites. The P. falciparum clones 3D7,
HB3, and IT4 were maintained in long-term in vitro cultures and antibody selected for IE surface
expression of speciﬁc PfEMP1 proteins as described previously (15, 51). In brief, we used the human
monoclonal IgG antibody AB01 to select 3D7 IEs for the expression of PFD1235w (53). HB3 IEs were
similarly selected for surface expression of VAR03 using a rat antiserum against M8, and IT4 IEs were
selected for expression of VAR13 by a rat antiserum against N27 (33). In all cases, expression of the
required PfEMP1 on the surface of mature IEs puriﬁed on a VarioMACS separator was monitored by ﬂow
FIG 6 ICAM-1-speciﬁc adhesion of erythrocytes infected by patient P. falciparum isolates and inhibition
of ICAM-1-adhering IEs by M6pep/M9pep-speciﬁc antibody. (A) Adhesion of 33 patient isolates to ICAM-1
under physiologic ﬂow; (B) antibody-mediated inhibition (25%) of ICAM-1-speciﬁc IE adhesion among
the 22 patient isolates adhering (10 adherent IEs/mm2) to ICAM-1 under physiologic ﬂow. The isolates
were tested in one experiment with ﬁve technical replicates. Fewer than 0.25 IEs/mm2 bound to
uncoated channels. Isolates from patients with uncomplicated malaria (Œ), cerebral malaria (Œ), and
noncerebral severe disease () are indicated in both panels.
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cytometry using PfEMP1-speciﬁc antisera, essentially as described previously (51, 54). Only cultures with
60% antibody-labeled IEs were used.
In addition, primary isolates of P. falciparum parasites from 33 of the above-mentioned malaria
patients were cultured in vitro for up to 28 days (median and 25th and 75th percentile, 8, 2.5, and 13 days,
respectively) in Albumax (10%) (ThermoFisher Scientiﬁc), supplemented with NHS (2%), essentially as
described previously (55). The genotypic identity of the isolates was routinely veriﬁed by genotyping as
described previously (56), and Mycoplasma infection was regularly excluded using the MycoAlert
Mycoplasma detection kit (Lonza) according to the manufacturer’s instructions.
Adhesion of IEs to ICAM-1 under physiological ﬂow in vitro. Microslides (VI0.1) (Ibidi) were coated
with recombinant Fc-tagged ICAM-1 protein (50) (50 g/ml, 4°C, overnight) and blocked using PBS plus
2% bovine serum albumin (BSA). Parasite suspensions, adjusted to 3% parasitemia and 1% hematocrit in
RPMI 1640 supplemented with 2% NHS (pH 7.2), were ﬂowed over the coated slides (5 min) at a shear
stress of 1 dyn/cm2 as described previously (35). The numbers of bound IE/mm2 in ﬁve separate ﬁelds
were counted, using a Leica inverted phase-contrast microscope (20 magniﬁcation). To assess the
capacity of afﬁnity-puriﬁed DBL-speciﬁc IgG to inhibit adhesion, IEs selected for expression of particular
PfEMP1 variants were preincubated with the puriﬁed IgG (15 min, room temperature). The receptor
speciﬁcity of the IE adhesion observed was veriﬁed by preincubating the ICAM-1-coated ﬂow channels
with an ICAM-1-speciﬁc antibody (40 g/ml, clone 15.2; AbD Serotec).
The inhibition of ICAM-1-adhering erythrocytes (10 adherent IEs/mm2) infected with primary P.
falciparum ﬁeld isolates was tested using pooled rat antisera (1:100 dilution) to two peptides represent-
ing the ICAM-1-binding motifs in M6 (M6pep) and M9 (M9pep). A minimum of three independent
TABLE 3 Recombinant proteins used in the study
Domain
ID Genome PfEMP1
Domain
subtypea
Binds
ICAM-1b Groupc Gene sourcei
M1 3D7 PF11_0521d DBL3_D4 Yes j A
M2 BM048 JF712902 DBL3_D4 Yes j A
M3 BM066 JF712903 DBL3_D4 Yes j A
M4 BM021 JF712900 DBL3_D4 Yes j A
M5 BM057 JN037695 DBL3_D4 Yes j A
M6 3D7 PFD1235we DBL3_D4 Yes j A
M7 MN35 KJ866957 DBL3_D4 Yes j A
M8 HB3 VAR03 DBL3_D4 Yes j A
M9 Dd2 VAR32 f DBL1_D4 Yes j A
M10 MN56 KM364031 DBL1_D4 Yes j A
M11 A4395 KJ866958 DBL3 Yes j A
M12 1914 AFJ66668 DBL1_D4 Yes j A
M13 BM028 JF712901 DBL3_D4 Yes j A
M14 KM364033 DBL3 Yes j A
M15 MN062 KF984156 DBL1_D4 Yes j A
N21 CDO61797 No k A Synthetic gene (Euroﬁns Genomics)
N22 CDO63496 No k A Synthetic gene (Euroﬁns Genomics)
N23 Dd2 VAR25 DBL11_D4 No j A
N24 HB3 VAR1CSA DBL11_D4 No j A
N25 3D7 PF13_0003 DBL9_D8 No j A
N26 A4393 KJ866959 DBL3 No j A
N27 IT4 IT4VAR13g DBL3_D4 Yes j,l B
N28 1983 JQ691647 DBL3_D4 No j A
N29 MN35 KM364034 DBL6 No j A
N30 Dd2 VAR52 DBL7_D4 No j A
N31 HB3 VAR01 DBL7_D4 No j A
N32 1983 JQ691649 DBL6_D4 No j A
N33 IT4 IT4VAR16h DBL5_D4 Yes j,l B Genomic DNA using forward and reverse
primers: 5=-ATCCCGGGTGTGCTGAACCTAATGG
TAG-3= and
5=-ATGCGGCCGCTACAAGCACACGCATCATC-3=
aNomenclature as described in reference 15.
b“Yes” indicates DBL_motif domains that bind ICAM-1 (M1 to M15, N27, and N33); “no” indicates domains that do not bind ICAM-1 (the remainder).
cAll domains were group A except for two group B DBL domains as indicated (N27 and N33).
dAlso known as PF3D7_1150400.
eAlso known as PF3D7_0425800.
fAlso known as KOB85388.
gAlso known as ABM88750.
hAlso known as AAS89259.
iFrom genomic DNA, using previously described primers (15, 33), except where indicated.
jData from reference 33.
kUnpublished data.
lData from reference 61.
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experiments were completed for each of the tested laboratory clones (3D7, HB3, IT4), whereas each of
the ﬁeld isolates was tested in one experiment with ﬁve technical replicates. All assays were deidentiﬁed
for the operator.
Immunoﬂuorescence microscopy of IEs labeled with PfEMP1-speciﬁc antibodies. Immunoﬂuo-
rescence microscopy was done essentially as described previously (57). Brieﬂy, aliquots (50 l) of
erythrocytes infected by parasites expressing PFD1235w, HB3VAR03, or IT4VAR13 were adjusted to 5%
parasitemia and resuspended in PBS containing 1% Ig-free BSA (Sigma-Aldrich). Antisera were added
(1:50 dilution), and the suspensions were incubated on ice (1 h). Following three washes, cells were
resuspended and labeled with anti-rat–ﬂuorescein isothiocyanate (FITC) secondary antibody (1:500) and
incubated on ice for 1 h. Cells were washed three times, and thin smears were made. Nuclei were
visualized by adding 5 l ProLong Gold antifade mountant (ThermoFisher Scientiﬁc) prior to the addition
of coverslips. Immunoﬂuorescence was visualized with a Nikon Eclipse TE2000 microscope equipped
with a 63 objective.
Bioinformatics. Multiple alignments of DBL domains known to bind ICAM-1 were made using
MUSCLE v.3.7 software (58), and sequence distance trees were made with MEGA software (59). A
WebLogo 3 sequence logo (60) of the ICAM-1-binding motif was generated based on alignment of
the included DBL_motif domains (Table 3) with the consensus motif I(V/L)X3N(E)GG(P/A)XYX27GP
PX3H (15, 33).
Statistics. We used Pearson’s product moment correlation (r) or Spearman’s rank-order correlation
(rs) to evaluate parameter association and one-way analysis of variance (F), the Kruskal-Wallis one-way
analysis of variance on ranks (T), and the Mann-Whitney test (U) to test for intergroup differences.
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